APO Research
Talk to an analyst

APO RESEARCH · REPORT

ADC Drug CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global ADC Drug CDMO Service Market Analysis and Forecast 2026-2032

5 June 2026194 pages

Choose your research edition.

Industry ResearchADC Drug CDMO Service Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal ADC Drug CDMO Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal ADC Drug CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ADC Drug CDMO Service Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal ADC Drug CDMO Service Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global ADC Drug CDMO Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for ADC Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for ADC Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for ADC Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for ADC Drug CDMO Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of ADC Drug CDMO Service include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora and Aji Bio-Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for ADC Drug CDMO Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of ADC Drug CDMO Service, also provides the revenue of main regions and countries. Of the upcoming market potential for ADC Drug CDMO Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the ADC Drug CDMO Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global ADC Drug CDMO Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for ADC Drug CDMO Service revenue, projected growth trends, production technology, application and end-user industry.

ADC Drug CDMO Service Segment by Company

Lonza Group

Merck KGaA

WuXi XDC

Abbvie

Piramal Pharma Solutions

Catalent

Sterling Pharma Solutions

Axplora

Aji Bio-Pharma

BSP Pharmaceuticals

Cerbios-Pharma

Goodwin Biotechnology

TOT Biopharm

Huadong Medicine

Innovent Biologics

Shanghai Henlius Biotech

ADC Drug CDMO Service Segment by Type

Cleavable Linkers

Non-cleavable Linkers

ADC Drug CDMO Service Segment by Application

Small and Medium-sized Pharmaceutical Companies

Large Pharmaceutical Companies

ADC Drug CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADC Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ADC Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADC Drug CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of ADC Drug CDMO Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of ADC Drug CDMO Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, ADC Drug CDMO Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global ADC Drug CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cleavable Linkers Major Player Table 3. Non-cleavable Linkers Major Player Table 4. Global ADC Drug CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Small and Medium-sized Pharmaceutical Companies Major Player Table 6. Large Pharmaceutical Companies Major Player Table 7. ADC Drug CDMO Service Industry Trends Table 8. ADC Drug CDMO Service Industry Drivers Table 9. ADC Drug CDMO Service Industry Opportunities and Challenges Table 10. ADC Drug CDMO Service Industry Restraints Table 11. Global ADC Drug CDMO Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global ADC Drug CDMO Service Market Size by Region (2021-2026) & (US$ Million) Table 13. Global ADC Drug CDMO Service Market Share by Region (2021-2026) Table 14. Global ADC Drug CDMO Service Market Size by Region (2027-2032) & (US$ Million) Table 15. Global ADC Drug CDMO Service Market Share by Region (2027-2032) Table 16. Global ADC Drug CDMO Service Revenue by Players (US$ Million) & (2021-2026) Table 17. Global ADC Drug CDMO Service Revenue Market Share by Players (2021-2026) Table 18. Global ADC Drug CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global ADC Drug CDMO Service Key Players Headquarters & Area Served Table 20. Global ADC Drug CDMO Service Players, Product Type & Application Table 21. Global ADC Drug CDMO Service Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global ADC Drug CDMO Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global ADC Drug CDMO Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global ADC Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 26. Global ADC Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 27. Global ADC Drug CDMO Service Revenue Market Share by Type (2021-2026) Table 28. Global ADC Drug CDMO Service Revenue Market Share by Type (2027-2032) Table 29. Global ADC Drug CDMO Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global ADC Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 31. Global ADC Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 32. Global ADC Drug CDMO Service Revenue Market Share by Application (2021-2026) Table 33. Global ADC Drug CDMO Service Revenue Market Share by Application (2027-2032) Table 34. Lonza Group Company Information Table 35. Lonza Group Business Overview Table 36. Lonza Group ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Lonza Group ADC Drug CDMO Service Product Portfolio Table 38. Lonza Group Recent Development Table 39. Merck KGaA Company Information Table 40. Merck KGaA Business Overview Table 41. Merck KGaA ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Merck KGaA ADC Drug CDMO Service Product Portfolio Table 43. Merck KGaA Recent Development Table 44. WuXi XDC Company Information Table 45. WuXi XDC Business Overview Table 46. WuXi XDC ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. WuXi XDC ADC Drug CDMO Service Product Portfolio Table 48. WuXi XDC Recent Development Table 49. Abbvie Company Information Table 50. Abbvie Business Overview Table 51. Abbvie ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Abbvie ADC Drug CDMO Service Product Portfolio Table 53. Abbvie Recent Development Table 54. Piramal Pharma Solutions Company Information Table 55. Piramal Pharma Solutions Business Overview Table 56. Piramal Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Piramal Pharma Solutions ADC Drug CDMO Service Product Portfolio Table 58. Piramal Pharma Solutions Recent Development Table 59. Catalent Company Information Table 60. Catalent Business Overview Table 61. Catalent ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Catalent ADC Drug CDMO Service Product Portfolio Table 63. Catalent Recent Development Table 64. Sterling Pharma Solutions Company Information Table 65. Sterling Pharma Solutions Business Overview Table 66. Sterling Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Sterling Pharma Solutions ADC Drug CDMO Service Product Portfolio Table 68. Sterling Pharma Solutions Recent Development Table 69. Axplora Company Information Table 70. Axplora Business Overview Table 71. Axplora ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Axplora ADC Drug CDMO Service Product Portfolio Table 73. Axplora Recent Development Table 74. Aji Bio-Pharma Company Information Table 75. Aji Bio-Pharma Business Overview Table 76. Aji Bio-Pharma ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Aji Bio-Pharma ADC Drug CDMO Service Product Portfolio Table 78. Aji Bio-Pharma Recent Development Table 79. BSP Pharmaceuticals Company Information Table 80. BSP Pharmaceuticals Business Overview Table 81. BSP Pharmaceuticals ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. BSP Pharmaceuticals ADC Drug CDMO Service Product Portfolio Table 83. BSP Pharmaceuticals Recent Development Table 84. Cerbios-Pharma Company Information Table 85. Cerbios-Pharma Business Overview Table 86. Cerbios-Pharma ADC Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Cerbios-Pharma ADC Drug CDMO Service Product Portfolio Table 88. Cerbios-Pharma Recent Development Table 89. Goodwin Biotechnology Company Information Table 90. Goodwin Biotechnology Business Overview Table 91. Goodwin Biotechnology ADC Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Goodwin Biotechnology ADC Drug CDMO Service Product Portfolio Table 93. Goodwin Biotechnology Recent Development Table 94. TOT Biopharm Company Information Table 95. TOT Biopharm Business Overview Table 96. TOT Biopharm ADC Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. TOT Biopharm ADC Drug CDMO Service Product Portfolio Table 98. TOT Biopharm Recent Development Table 99. Huadong Medicine Company Information Table 100. Huadong Medicine Business Overview Table 101. Huadong Medicine ADC Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Huadong Medicine ADC Drug CDMO Service Product Portfolio Table 103. Huadong Medicine Recent Development Table 104. Innovent Biologics Company Information Table 105. Innovent Biologics Business Overview Table 106. Innovent Biologics ADC Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Innovent Biologics ADC Drug CDMO Service Product Portfolio Table 108. Innovent Biologics Recent Development Table 109. Shanghai Henlius Biotech Company Information Table 110. Shanghai Henlius Biotech Business Overview Table 111. Shanghai Henlius Biotech ADC Drug CDMO Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Shanghai Henlius Biotech ADC Drug CDMO Service Product Portfolio Table 113. Shanghai Henlius Biotech Recent Development Table 114. North America ADC Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 115. North America ADC Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 116. North America ADC Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 117. North America ADC Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 118. North America ADC Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America ADC Drug CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 120. North America ADC Drug CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe ADC Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe ADC Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe ADC Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe ADC Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe ADC Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe ADC Drug CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe ADC Drug CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 128. China ADC Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 129. China ADC Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 130. China ADC Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 131. China ADC Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia ADC Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia ADC Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia ADC Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia ADC Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia ADC Drug CDMO Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia ADC Drug CDMO Service Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia ADC Drug CDMO Service Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA ADC Drug CDMO Service Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA ADC Drug CDMO Service Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA ADC Drug CDMO Service Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA ADC Drug CDMO Service Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA ADC Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA ADC Drug CDMO Service Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA ADC Drug CDMO Service Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. ADC Drug CDMO Service Image Figure 2. Global ADC Drug CDMO Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ADC Drug CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cleavable Linkers Image Figure 5. Non-cleavable Linkers Image Figure 6. Global ADC Drug CDMO Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global ADC Drug CDMO Service Market Size Share 2021 VS 2025 VS 2032 Figure 8. Small and Medium-sized Pharmaceutical Companies Image Figure 9. Large Pharmaceutical Companies Image Figure 10. Global ADC Drug CDMO Service Market Size (US$ Million) & (2021-2032) Figure 11. Global ADC Drug CDMO Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global ADC Drug CDMO Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global ADC Drug CDMO Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global ADC Drug CDMO Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global ADC Drug CDMO Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global ADC Drug CDMO Service Revenue Market Share by Type (2021-2032) Figure 18. Global ADC Drug CDMO Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global ADC Drug CDMO Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global ADC Drug CDMO Service Revenue Market Share by Application (2021-2032) Figure 21. North America ADC Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America ADC Drug CDMO Service Revenue Share by Type (2021-2032) Figure 23. North America ADC Drug CDMO Service Revenue Share by Application (2021-2032) Figure 24. North America ADC Drug CDMO Service Revenue Share by Country (2021-2032) Figure 25. United States ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe ADC Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe ADC Drug CDMO Service Revenue Share by Type (2021-2032) Figure 30. Europe ADC Drug CDMO Service Revenue Share by Application (2021-2032) Figure 31. Europe ADC Drug CDMO Service Revenue Share by Country (2021-2032) Figure 32. Germany ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China ADC Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China ADC Drug CDMO Service Revenue Share by Type (2021-2032) Figure 42. China ADC Drug CDMO Service Revenue Share by Application (2021-2032) Figure 43. Asia ADC Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia ADC Drug CDMO Service Revenue Share by Type (2021-2032) Figure 45. Asia ADC Drug CDMO Service Revenue Share by Application (2021-2032) Figure 46. Asia ADC Drug CDMO Service Revenue Share by Region (2021-2032) Figure 47. Japan ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA ADC Drug CDMO Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA ADC Drug CDMO Service Revenue Share by Type (2021-2032) Figure 55. SAMEA ADC Drug CDMO Service Revenue Share by Application (2021-2032) Figure 56. SAMEA ADC Drug CDMO Service Revenue Share by Country (2021-2032) Figure 57. Brazil ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt ADC Drug CDMO Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Cleavable Linkers
  • Non-cleavable Linkers
Applications
  • Small and Medium-sized Pharmaceutical Companies
  • Large Pharmaceutical Companies
Companies covered
  • Lonza Group
  • Merck KGaA
  • WuXi XDC
  • Abbvie
  • Piramal Pharma Solutions
  • Catalent
  • Sterling Pharma Solutions
  • Axplora
  • Aji Bio-Pharma
  • BSP Pharmaceuticals
  • Cerbios-Pharma
  • Goodwin Biotechnology
  • TOT Biopharm
  • Huadong Medicine
  • Innovent Biologics
  • Shanghai Henlius Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 ADC Drug CDMO Service Market by Type
  3. 1.2.1 Global ADC Drug CDMO Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cleavable Linkers
  5. 1.2.3 Non-cleavable Linkers
  6. 1.3 ADC Drug CDMO Service Market by Application
  7. 1.3.1 Global ADC Drug CDMO Service Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Small and Medium-sized Pharmaceutical Companies
  9. 1.3.3 Large Pharmaceutical Companies
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 ADC Drug CDMO Service Market Dynamics
  1. 2.1 ADC Drug CDMO Service Industry Trends
  2. 2.2 ADC Drug CDMO Service Industry Drivers
  3. 2.3 ADC Drug CDMO Service Industry Opportunities and Challenges
  4. 2.4 ADC Drug CDMO Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global ADC Drug CDMO Service Market Perspective (2021-2032)
  2. 3.2 Global ADC Drug CDMO Service Growth Trends by Region
  3. 3.2.1 Global ADC Drug CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global ADC Drug CDMO Service Market Size by Region (2021-2026)
  5. 3.2.3 Global ADC Drug CDMO Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global ADC Drug CDMO Service Revenue by Players
  2. 4.1.1 Global ADC Drug CDMO Service Revenue by Players (2021-2026)
  3. 4.1.2 Global ADC Drug CDMO Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global ADC Drug CDMO Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global ADC Drug CDMO Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global ADC Drug CDMO Service Key Players Headquarters & Area Served
  7. 4.4 Global ADC Drug CDMO Service Players, Product Type & Application
  8. 4.5 Global ADC Drug CDMO Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global ADC Drug CDMO Service Market CR5 and HHI
  11. 4.6.3 2025 ADC Drug CDMO Service Tier 1, Tier 2, and Tier 3
5 ADC Drug CDMO Service Market Size by Type
  1. 5.1 Global ADC Drug CDMO Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global ADC Drug CDMO Service Revenue by Type (2021-2032)
  3. 5.3 Global ADC Drug CDMO Service Revenue Market Share by Type (2021-2032)
6 ADC Drug CDMO Service Market Size by Application
  1. 6.1 Global ADC Drug CDMO Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global ADC Drug CDMO Service Revenue by Application (2021-2032)
  3. 6.3 Global ADC Drug CDMO Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza Group
  2. 7.1.1 Lonza Group Company Information
  3. 7.1.2 Lonza Group Business Overview
  4. 7.1.3 Lonza Group ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza Group ADC Drug CDMO Service Product Portfolio
  6. 7.1.5 Lonza Group Recent Developments
  7. 7.2 Merck KGaA
  8. 7.2.1 Merck KGaA Company Information
  9. 7.2.2 Merck KGaA Business Overview
  10. 7.2.3 Merck KGaA ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck KGaA ADC Drug CDMO Service Product Portfolio
  12. 7.2.5 Merck KGaA Recent Developments
  13. 7.3 WuXi XDC
  14. 7.3.1 WuXi XDC Company Information
  15. 7.3.2 WuXi XDC Business Overview
  16. 7.3.3 WuXi XDC ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 WuXi XDC ADC Drug CDMO Service Product Portfolio
  18. 7.3.5 WuXi XDC Recent Developments
  19. 7.4 Abbvie
  20. 7.4.1 Abbvie Company Information
  21. 7.4.2 Abbvie Business Overview
  22. 7.4.3 Abbvie ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Abbvie ADC Drug CDMO Service Product Portfolio
  24. 7.4.5 Abbvie Recent Developments
  25. 7.5 Piramal Pharma Solutions
  26. 7.5.1 Piramal Pharma Solutions Company Information
  27. 7.5.2 Piramal Pharma Solutions Business Overview
  28. 7.5.3 Piramal Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Piramal Pharma Solutions ADC Drug CDMO Service Product Portfolio
  30. 7.5.5 Piramal Pharma Solutions Recent Developments
  31. 7.6 Catalent
  32. 7.6.1 Catalent Company Information
  33. 7.6.2 Catalent Business Overview
  34. 7.6.3 Catalent ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Catalent ADC Drug CDMO Service Product Portfolio
  36. 7.6.5 Catalent Recent Developments
  37. 7.7 Sterling Pharma Solutions
  38. 7.7.1 Sterling Pharma Solutions Company Information
  39. 7.7.2 Sterling Pharma Solutions Business Overview
  40. 7.7.3 Sterling Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sterling Pharma Solutions ADC Drug CDMO Service Product Portfolio
  42. 7.7.5 Sterling Pharma Solutions Recent Developments
  43. 7.8 Axplora
  44. 7.8.1 Axplora Company Information
  45. 7.8.2 Axplora Business Overview
  46. 7.8.3 Axplora ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Axplora ADC Drug CDMO Service Product Portfolio
  48. 7.8.5 Axplora Recent Developments
  49. 7.9 Aji Bio-Pharma
  50. 7.9.1 Aji Bio-Pharma Company Information
  51. 7.9.2 Aji Bio-Pharma Business Overview
  52. 7.9.3 Aji Bio-Pharma ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Aji Bio-Pharma ADC Drug CDMO Service Product Portfolio
  54. 7.9.5 Aji Bio-Pharma Recent Developments
  55. 7.10 BSP Pharmaceuticals
  56. 7.10.1 BSP Pharmaceuticals Company Information
  57. 7.10.2 BSP Pharmaceuticals Business Overview
  58. 7.10.3 BSP Pharmaceuticals ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 BSP Pharmaceuticals ADC Drug CDMO Service Product Portfolio
  60. 7.10.5 BSP Pharmaceuticals Recent Developments
  61. 7.11 Cerbios-Pharma
  62. 7.11.1 Cerbios-Pharma Company Information
  63. 7.11.2 Cerbios-Pharma Business Overview
  64. 7.11.3 Cerbios-Pharma ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Cerbios-Pharma ADC Drug CDMO Service Product Portfolio
  66. 7.11.5 Cerbios-Pharma Recent Developments
  67. 7.12 Goodwin Biotechnology
  68. 7.12.1 Goodwin Biotechnology Company Information
  69. 7.12.2 Goodwin Biotechnology Business Overview
  70. 7.12.3 Goodwin Biotechnology ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Goodwin Biotechnology ADC Drug CDMO Service Product Portfolio
  72. 7.12.5 Goodwin Biotechnology Recent Developments
  73. 7.13 TOT Biopharm
  74. 7.13.1 TOT Biopharm Company Information
  75. 7.13.2 TOT Biopharm Business Overview
  76. 7.13.3 TOT Biopharm ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 TOT Biopharm ADC Drug CDMO Service Product Portfolio
  78. 7.13.5 TOT Biopharm Recent Developments
  79. 7.14 Huadong Medicine
  80. 7.14.1 Huadong Medicine Company Information
  81. 7.14.2 Huadong Medicine Business Overview
  82. 7.14.3 Huadong Medicine ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Huadong Medicine ADC Drug CDMO Service Product Portfolio
  84. 7.14.5 Huadong Medicine Recent Developments
  85. 7.15 Innovent Biologics
  86. 7.15.1 Innovent Biologics Company Information
  87. 7.15.2 Innovent Biologics Business Overview
  88. 7.15.3 Innovent Biologics ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Innovent Biologics ADC Drug CDMO Service Product Portfolio
  90. 7.15.5 Innovent Biologics Recent Developments
  91. 7.16 Shanghai Henlius Biotech
  92. 7.16.1 Shanghai Henlius Biotech Company Information
  93. 7.16.2 Shanghai Henlius Biotech Business Overview
  94. 7.16.3 Shanghai Henlius Biotech ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Shanghai Henlius Biotech ADC Drug CDMO Service Product Portfolio
  96. 7.16.5 Shanghai Henlius Biotech Recent Developments
8 North America
  1. 8.1 North America ADC Drug CDMO Service Revenue (2021-2032)
  2. 8.2 North America ADC Drug CDMO Service Revenue by Type (2021-2032)
  3. 8.2.1 North America ADC Drug CDMO Service Revenue by Type (2021-2026)
  4. 8.2.2 North America ADC Drug CDMO Service Revenue by Type (2027-2032)
  5. 8.3 North America ADC Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 8.4 North America ADC Drug CDMO Service Revenue by Application (2021-2032)
  7. 8.4.1 North America ADC Drug CDMO Service Revenue by Application (2021-2026)
  8. 8.4.2 North America ADC Drug CDMO Service Revenue by Application (2027-2032)
  9. 8.5 North America ADC Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 8.6 North America ADC Drug CDMO Service Revenue by Country
  11. 8.6.1 North America ADC Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America ADC Drug CDMO Service Revenue by Country (2021-2026)
  13. 8.6.3 North America ADC Drug CDMO Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe ADC Drug CDMO Service Revenue (2021-2032)
  2. 9.2 Europe ADC Drug CDMO Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe ADC Drug CDMO Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe ADC Drug CDMO Service Revenue by Type (2027-2032)
  5. 9.3 Europe ADC Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe ADC Drug CDMO Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe ADC Drug CDMO Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe ADC Drug CDMO Service Revenue by Application (2027-2032)
  9. 9.5 Europe ADC Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe ADC Drug CDMO Service Revenue by Country
  11. 9.6.1 Europe ADC Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe ADC Drug CDMO Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe ADC Drug CDMO Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China ADC Drug CDMO Service Revenue (2021-2032)
  2. 10.2 China ADC Drug CDMO Service Revenue by Type (2021-2032)
  3. 10.2.1 China ADC Drug CDMO Service Revenue by Type (2021-2026)
  4. 10.2.2 China ADC Drug CDMO Service Revenue by Type (2027-2032)
  5. 10.3 China ADC Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 10.4 China ADC Drug CDMO Service Revenue by Application (2021-2032)
  7. 10.4.1 China ADC Drug CDMO Service Revenue by Application (2021-2026)
  8. 10.4.2 China ADC Drug CDMO Service Revenue by Application (2027-2032)
  9. 10.5 China ADC Drug CDMO Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia ADC Drug CDMO Service Revenue (2021-2032)
  2. 11.2 Asia ADC Drug CDMO Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia ADC Drug CDMO Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia ADC Drug CDMO Service Revenue by Type (2027-2032)
  5. 11.3 Asia ADC Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia ADC Drug CDMO Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia ADC Drug CDMO Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia ADC Drug CDMO Service Revenue by Application (2027-2032)
  9. 11.5 Asia ADC Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia ADC Drug CDMO Service Revenue by Country
  11. 11.6.1 Asia ADC Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia ADC Drug CDMO Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia ADC Drug CDMO Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA ADC Drug CDMO Service Revenue (2021-2032)
  2. 12.2 SAMEA ADC Drug CDMO Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA ADC Drug CDMO Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA ADC Drug CDMO Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA ADC Drug CDMO Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA ADC Drug CDMO Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA ADC Drug CDMO Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA ADC Drug CDMO Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA ADC Drug CDMO Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA ADC Drug CDMO Service Revenue by Country
  11. 12.6.1 SAMEA ADC Drug CDMO Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA ADC Drug CDMO Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA ADC Drug CDMO Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst